RxDoctor Payments Data

Nadine Pechter, MD

Internal Medicine · Raleigh, NCNPI 1235458423

Payments from drug & device makers

$891in general payments, 2019–2025

Across 49 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$230
  • AbbVie$114
  • Abbott$101
  • Novo Nordisk$97
  • Pfizer$54
  • Astellas Pharma US Inc$43
  • plus $253 from 12 others

What the payments were for

  • Food & beverage$891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$891 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$121,374
Medicare patients
242
Services billed
1,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$69,138
JardianceEmpagliflozin47$65,516
JanuviaSitagliptin Phosphate42$54,147
MounjaroTirzepatide29$43,936
EliquisApixaban23$24,984
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,745
MyrbetriqMirabegron11$6,524
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$5,655
XareltoRivaroxaban11$5,335
Breo ElliptaFluticasone/Vilanterol12$5,262
Levothyroxine Sodium335$4,885
SynthroidLevothyroxine Sodium37$4,868
Soliqua 100-33Insulin Glargine/Lixisenatide12$4,307
Risedronate Sodium33$3,712
Ezetimibe118$2,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$97$69,13839 claims
PfizerEliquis$54$24,98423 claims
GSKTrelegy Ellipta, Breo Ellipta$30$19,00731 claims
Astellas Pharma US IncMyrbetriq$43$6,52411 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$11$4,885335 claims
AbbVieSynthroid$114$4,86837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →